Understand the source comparison
Wolverine Stack Animal vs Human Research: Efficacy Comparison
MK-677 (Ibutamoren) 8–12kg lean mass gain (24-week rodent studies, scaled) 1.1kg lean mass gain (24-month human trial, elderly subjects) Yes. IGF-1 elevation confirmed Investigational (not FDA-approved) GHRP-2 680% increase in pulsatile GH release (young rats)
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- MK-677 (Ibutamoren)
- 8–12kg lean mass gain (24-week rodent studies, scaled)
- 1.1kg lean mass gain (24-month human trial, elderly subjects)
- Yes. IGF-1 elevation confirmed
- Investigational (not FDA-approved)
- GHRP-2
- 680% increase in pulsatile GH release (young rats)
- 4× GH peak elevation (single-dose human study)
- Partially. Acute GH response confirmed, chronic effects unknown
- Research chemical (no human approval)
- BPC-157
- 340% faster wound closure (rodent tendon injury models)
- No published human trials
- No. VEGF modulation proposed but unconfirmed in humans
- Research chemical (veterinary use only)
- TB-500 (Thymosin Beta-4)
- 60% reduction in infarct size (rodent cardiac injury models)
- No. Actin-binding mechanism demonstrated in vitro only
- Research chemical (Phase I never completed)
- MOTS-C (Mitochondrial peptide)
- 25% increase in endurance capacity (aged mice)
- No. AMPK activation proposed but unproven in humans
- Research chemical (pre-clinical stage)